Exenatide in type 2 diabetes

Lancet. 2010 Sep 25;376(9746):1052-3; author reply 1053. doi: 10.1016/S0140-6736(10)61485-7.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Biomarkers / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Energy Intake
  • Exenatide
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / adverse effects*
  • Hypoglycemic Agents / pharmacology
  • Insulin / analogs & derivatives
  • Insulin / pharmacology
  • Insulin Glargine
  • Insulin, Long-Acting
  • Peptides / administration & dosage
  • Peptides / adverse effects*
  • Peptides / pharmacology
  • Quality of Life
  • Venoms / administration & dosage
  • Venoms / adverse effects*
  • Venoms / pharmacology

Substances

  • Biomarkers
  • Hypoglycemic Agents
  • Insulin
  • Insulin, Long-Acting
  • Peptides
  • Venoms
  • Insulin Glargine
  • Exenatide